Trials / Completed
CompletedNCT05463432
A Study of HR19024 in Subjects With Advanced Solid Tumor
An Open-label Phase 1a Study of the Safety and Tolerability of HR19024 Injection in Subjects With Advanced Solid Tumor
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety，tolerability，pharmacokinetic characteristics and preliminary efficacy of HR19024 injection in the treatment of advanced solid tumor
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HR19024 | Intravenous infusion |
Timeline
- Start date
- 2022-08-10
- Primary completion
- 2024-10-22
- Completion
- 2024-10-22
- First posted
- 2022-07-19
- Last updated
- 2025-03-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05463432. Inclusion in this directory is not an endorsement.